ABIVAX Société Anonyme 過去の業績

過去基準チェック /06

ABIVAX Société Anonymeの収益は年間平均-40.6%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間19.3% 62.5%割合で増加しています。

主要情報

-40.6%

収益成長率

-7.7%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	62.5%
株主資本利益率	-140.3%
ネット・マージン	-1,964.6%
次回の業績アップデート	07 Nov 2024

Recent updates

収支内訳

ABIVAX Société Anonyme の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:AAVX.F 収益、費用、利益 ( )EUR Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	9	-177	44	135
31 Mar 24	7	-163	36	119
31 Dec 23	4	-148	29	103
30 Sep 23	4	-120	21	84
30 Jun 23	4	-92	12	66
31 Mar 23	4	-76	10	57
31 Dec 22	4	-61	7	48
30 Sep 22	8	-54	6	56
30 Jun 22	2	-47	4	63
31 Mar 22	1	-45	5	55
31 Dec 21	4	-42	6	48
30 Sep 21	0	-41	6	24
30 Jun 21	0	-39	6	0
31 Mar 21	0	-38	6	0
31 Dec 20	0	-38	6	0
30 Sep 20	0	-35	5	0
30 Jun 20	0	-32	5	0
31 Mar 20	0	-31	5	0
31 Dec 19	0	-31	5	0
30 Sep 19	0	-27	5	0
30 Jun 19	0	-23	5	0
31 Mar 19	1	-19	5	0
31 Dec 18	1	-16	4	0
30 Sep 18	1	-14	4	0
30 Jun 18	1	-13	4	0
31 Mar 18	1	-12	4	0
31 Dec 17	0	-11	4	0
30 Sep 17	0	-11	4	0
30 Jun 17	0	-12	4	0
31 Mar 17	0	-13	4	0
31 Dec 16	0	-14	4	0
30 Sep 16	0	-16	4	0
30 Jun 16	0	-17	4	0
31 Mar 16	0	-17	4	0
31 Dec 15	0	-16	3	0
30 Sep 15	0	-14	3	0
30 Jun 15	0	-12	3	0
31 Mar 15	0	-8	2	0
31 Dec 14	0	-5	2	0

質の高い収益: AAVX.Fは現在利益が出ていません。

利益率の向上: AAVX.Fは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: AAVX.Fは利益が出ておらず、過去 5 年間で損失は年間40.6%の割合で増加しています。

成長の加速: AAVX.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: AAVX.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: AAVX.Fは現在利益が出ていないため、自己資本利益率 ( -140.29% ) はマイナスです。

ABIVAX Société Anonyme 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06